Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:


    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433
    ir@vantiatherapeutics.com         +44(0)7515-397176


    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk / mark.swallow@citigatedr.co.uk /
    helena.galilee@citigatedr.c
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... NC (PRWEB) November 25, 2014 ... Intensity Focused Ultrasound (HIFU) devices, recently participated in ... Small Renal Mass 360° .” Key opinion leaders ... therapeutic advances related to small renal masses while ... about different ablative technologies in hands-on labs. Attendees ...
(Date:11/26/2014)... Miles Holder, formerly of Micron Research and ... team as Sales/Marketing Manager. Mr. Holder has over 25 ... the graphite industry. , “We are thrilled to be ... Trinkley, VP of Market and Product Development for Graphel ... the graphite industry, along with his proven track record ...
(Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... SAN DIEGO, Sept. 27, 2011 Verenium Corporation (Nasdaq: ... developing and commercializing high-performance enzymes, today announced that it ... an aggregate of $34.9 million in principal amount of ... repurchase of approximately $1.1 million in principal amount of ...
... Circassia Ltd, a specialty biopharmaceutical company focused ... results showing that its ToleroMune® hay fever vaccine ... on placebo.  The treatment was extremely well tolerated. ... phase II study conducted in 50 hay fever ...
... Chemical Engineering department and the Kavli institute of Delft ... electrons can move freely in layers of linked semiconductor ... will be very useful for the development of cheap ... their findings on Sunday 25 September on the website ...
Cached Biology Technology:Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial 2Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial 3TU Delft: cheap and efficient solar cell made possible by linked nanoparticles 2
(Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
(Date:11/6/2014)... groundbreaking paper from a team of Florida State University ... plants could adapt to and survive environmental swings such ... the latest issue of the journal The Plant ... of DNA and proteins) is organized in a cell ... genes are turned on and others are turned off. ...
(Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... WORCESTER, MA Scientists at the University of Massachusetts ... piecing together the short DNA reads produced by next-generation ... genome sequences. Job Dekker, PhD, and colleagues have shown ... accurately by measuring the frequency of interactions between DNA ...
... great number of women experience depression or anxiety while ... mood disorders may lead to long-term emotional and behavioral ... the fetal environment has a strong influence on offspring ... exact mechanisms by which this occurs are not completely ...
... 2013, Cleveland: Cleveland Clinic researchers Richard A. Padgett, Ph.D., and ... American Association for the Advancement of Science (AAAS). This year,s ... & Notes section of the journal Science on ... Department of Molecular Genetics at the Lerner Research Institute, was ...
Cached Biology News:University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 2University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 32 Cleveland Clinic researchers honored for contribution to science 2
Recombinant Mouse Noggin...
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... Complete kit for all types of yeast two-hybrid studies, ... Choice of two bait vectors ... , Triple reporter ... Complete set of controls: ...
Biology Products: